# A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

> **NCT03292133** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 11 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** EGF816
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT03292133
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-31
- **Primary completion:** 2021-12-31
- **Final completion:** 2025-03-04
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2025-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03292133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03292133, "A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03292133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*